Table 1.
Baseline characteristics of patients in the 878 well-balanced cohort
| Characteristic | CTX/NTZ plus CCRT N = 189 |
CCRT N = 689 |
P* |
|---|---|---|---|
| Gender | 0.382 | ||
| Female | 39 (20.6%) | 123 (17.9%) | |
| Male | 150 (79.4%) | 566 (82.1%) | |
| Age ——yr | 0.308^ | ||
| Median | 44.7 | 45.6 | |
| Range | 11.8-68.5 | 15.0-74.0 | |
| Karnofsky performance status score | 0.856 | ||
| 90-100 | 173 (91.5%) | 620 (90.0%) | |
| 70-80 | 16 (8.5%) | 69 (10.0%) | |
| T classification | 0.290 | ||
| T1 | 14 (7.4%) | 34 (4.9%) | |
| T2 | 33 (17.5%) | 95 (13.8%) | |
| T3 | 116 (61.4%) | 460 (66.8%) | |
| T4 | 26 (13.8%) | 100 (14.5%) | |
| N classification | 0.933 | ||
| No | 21 (11.1%) | 80 (11.6%) | |
| N1 | 86 (45.5%) | 328 (47.6%) | |
| N2 | 71 (37.6%) | 245 (35.6%) | |
| N3 | 11 (5.8%) | 36 (5.2%) | |
| Disease stage | 0.285 | ||
| II | 23 (12.2%) | 58 (8.4%) | |
| III | 130 (68.8%) | 497 (72.1%) | |
| IV | 36 (19.0%) | 134 (19.4%) |
CCRT = concurrent chemoradiotherapy; NTZ = Nimotuzumab; CTX = Cetuximab; *χ²test or Fisher's exact test. ^ Mann-Whitney U-test.